An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial

Chin J Integr Med. 2015 May;21(5):332-8. doi: 10.1007/s11655-015-2160-z. Epub 2015 Mar 17.

Abstract

Objective: To investigate the effectiveness of curcumin, a natural polyphenolic compound with antioxidant and anti-inflammatory activities, on the frequency of symptoms of anxiety and depression in obese individuals.

Methods: In this double blind, cross-over trial, 30 obese subjects were randomized to receive either curcumin (1 g/day) or placebo for a period of 30 days. Following a wash-out interval of 2 weeks, each subject was crossed over to the alternative regimen for a further 30 days. Severity of anxiety and depression was assessed at baseline and at weeks 4, 6 and 10 of the trial using the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scales, respectively.

Results: Mean BAI score was found to be significantly reduced following curcumin therapy (P=0.03). However, curcumin supplementation did not exert any significant impact on BDI scores (P=0.7).

Conclusion: Curcumin has a potential anti-anxiety effect in individuals with obesity.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anxiety / complications*
  • Anxiety / drug therapy*
  • Curcumin / therapeutic use*
  • Demography
  • Depression / complications*
  • Depression / drug therapy*
  • Female
  • Humans
  • Male
  • Obesity / complications*
  • Obesity / drug therapy*
  • Placebos
  • Psychiatric Status Rating Scales

Substances

  • Placebos
  • Curcumin